Core Viewpoint - The company Yifang Biotech (688382.SH) has announced an expected net loss of 292 million yuan for the fiscal year 2025, primarily due to high R&D investment and revenue composition changes [1]. Group 1: Financial Performance - The company anticipates a net loss of 292 million yuan for 2025 [1]. - The financial performance is significantly influenced by the intensity of R&D investments and the structure of revenue [1]. Group 2: R&D Progress - The company is advancing multiple core clinical projects, with several entering critical stages and showing positive progress [1]. - The oral selective estrogen receptor degrader (SERD) D0502 is undergoing a Phase III clinical trial for second-line treatment in China [1]. - The TYK2 inhibitor D-2570 has initiated clinical explorations in various autoimmune diseases, including a Phase II trial for ulcerative colitis and a Phase III trial for psoriasis in China, as well as a Phase I trial in the U.S. [1]. - The URAT1 inhibitor D-0120 has completed follow-up in a Phase II clinical trial in the U.S. and is expected to finish all research work by Q1 2026 [1]. Group 3: Preclinical Pipeline - The company has made significant progress in its preclinical pipeline, with two innovative candidates, WRN inhibitor YF087 and KIF18A inhibitor YF550, demonstrating strong anti-tumor potential in various preclinical studies [2]. - Ongoing IND supportive research is being conducted to prepare these candidates for clinical stages [2]. - The company continues to invest in early-stage R&D, including the development of other candidate drugs, innovative technology platforms, and early drug discovery to build momentum for long-term growth [2].

Core Viewpoint - The company Yifang Biotech (688382.SH) has announced an expected net loss of 292 million yuan for the fiscal year 2025, primarily due to high R&D investment and revenue composition changes [1]. Group 1: Financial Performance - The company anticipates a net loss of 292 million yuan for 2025 [1]. - The financial performance is significantly influenced by the intensity of R&D investments and the structure of revenue [1]. Group 2: R&D Progress - The company is advancing multiple core clinical projects, with several entering critical stages and showing positive progress [1]. - The oral selective estrogen receptor degrader (SERD) D0502 is undergoing a Phase III clinical trial for second-line treatment in China [1]. - The TYK2 inhibitor D-2570 has initiated clinical explorations in various autoimmune diseases, including a Phase II trial for ulcerative colitis and a Phase III trial for psoriasis in China, as well as a Phase I trial in the United States [1]. - The URAT1 inhibitor D-0120 has completed follow-up in a Phase II clinical trial in the U.S. and is expected to finish all research work by the first quarter of 2026 [1]. Group 3: Preclinical Pipeline - The company has made significant progress in its preclinical pipeline, with two innovative candidates, WRN inhibitor YF087 and KIF18A inhibitor YF550, demonstrating strong anti-tumor potential in various preclinical studies [2]. - Ongoing IND supportive research is being conducted to prepare these candidates for clinical stages [2]. - The company continues to invest in early-stage R&D, including the development of other candidate drugs, innovative technology platform construction, and early drug discovery to build momentum for long-term growth [2].